Initial safety experience of abciximab and heparin for acute ischemic stroke.
Mandava
Pitchaiah
P
Baylor College of Medicine and the Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA. pmandava@bcm.tmc.edu
Lick
Scott D
SD
Rahman
M A
MA
Langsjoen
Hans
H
Reddy
K V
KV
Nelson
Jeffrey
J
Kent
Thomas A
TA
D000077284:Abciximab; D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D002545:Brain Ischemia / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D006493:Heparin; D000077284:Abciximab